A Phase 1/2 First-in-Human Open-Label Dose Escalation Study of Talquetamab a Humanized GPRC5D x CD3 Bispecific Antibody in Subjects with Relapsed or Refractory Multiple Myeloma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Multiple Myeloma
  • Age: Between 18 Year(s) - 90 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Subjects with measurable multiple myeloma who have progressed on, or could not tolerate, all available established therapies. 2) Subject must have documented evidence of progressive disease based on investigator’s determination of response by the In

You may not be eligible for this study if the following are true:

  • 1) Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy. 2) Known to be seropositive for human immunodeficiency virus or acquired immune deficiency syn


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.